The Lundbeck Foundation divides its business activities in three areas:
The corporate activity covers direct holdings in mature innovative and knowledge based healthcare companies. In August 2000, the Foundation's shares in H. Lundbeck A/S and Chr. Hansen Holding A/S (now ALK-Abelló A/S) were transferred to Lundbeckfond Invest A/S. As of 1 January 2011, Lundbeckfond Invest A/S held 70% of the capital and voting rights in H. Lundbeck A/S, and 38% of the capital and 66% of the voting rights in ALK-Abelló A/S. Both companies are listed on NASDAQ OMX Copenhagen.
In 2011, Lundbeckfond Invest A/S bought 57% of Falck A/S as a new long term core direct holding.
Lundbeckfond Ventures was formed in 2009 as an evergreen life science venture fund to make direct investments primarily in pre-clinical and early clinical pharmaceutical and biopharmaceutical projects and companies. Besides new direct investments Lundbeckfond Ventures manages a portfolio of investments in biotech venture funds. On an annual basis, Lundbeckfond Ventures invests € 30-50 million.
The Lundbeck Foundation has an investment portfolio which is managed by its investment department in collaboration with external portfolio managers. The portfolio is invested internationally and diversified in various asset classes including equity, fixed income, credits, private equity, distressed debt and real estate. Real estate is partly invested through the 50% owned company Obel-LFI Ejendomme A/S.
The asset allocation is shown below: